Interet de la densitometrie osseuse dans le depistage et le suivi therapeu- tique des patients osteoporotiques: integration avec les facteurs cliniques et biologiques
Richy, F.; Lecart, Marie-Paule; Mawet, A.et al.
2006 • In Revue Médicale de Liège, 61 (5-6, May-Jun), p. 291-300
[en] The diagnosis of osteoporosis and the monitoring of antiosteoporosis therapies imply a better and more rational use of bone densitometry. The optimal prescription modalities of this fundamental examination are favorably correlated with the efficacy of modern therapeutics. The rationale of this article is to provide the general practitioner with a factual update on the diagnostic and prognostic use of bone densitometry.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
French
Title :
Interet de la densitometrie osseuse dans le depistage et le suivi therapeu- tique des patients osteoporotiques: integration avec les facteurs cliniques et biologiques
Alternative titles :
[en] Value of Bone Densitometry for the Diagnosis and Monitoring of Osteoporotic Patients: Integration with Biological and Clinical Risk Factors
Publication date :
2006
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
World Health Organization.- Prevention and management of osteoporosis. WHO Technical Report Series 921, WHO, Geneva, 2003.
Kanis JA, Melton U, Christiansen C, et al.- The diagnosis of osteoporosis. J Bone Miner Res, 1994, 9, 1137-1141.
Kanis JA, Torgerson D, Cooper C.- Comparison of the European and USA practice guidelines for Osteoporosis. Trends Endocrinol Metab, 2000, 1, 28-32.
Richy F, Bruyère O, Maassen P, et al.- Self-reported versus measured prevalence of osteoporosis. An age-stratified analysis of its diagnostic coverage. ACR/ARHP Annual Scientific Meeting, San-Diego CA, USA 2005. Arthritis Rheum, 2005, 52 Suppl.
Nelson HD, Helfand M, Woolf SH, et al.- Screening for postmenopausal osteoporosis: a review. Ann Intern Med, 2002, 137, 529-541.
National Osteoporosis Foundation: Physician's guide to prevention and treatment of osteoporosis 2003. http://www.nof.org/2003
North American Menopause Society. A decision tree for the use of estrogen replacement therapy or hormone replacement therapy in postmenopausal women: consensus opinion of The North American Menopause Society. Menopause, 2000, 7, 76-86.
Leib ES, Lewiecki EM, Binkley N, et al.- Official positions of the International Society for Clinical Densitometry. J Clin Densitom, 2004, 7, 1-6.
Lydick E, Cook K, Turpin J, et al.- Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care, 1998, 4, 37-48.
Khan AA, Bachrach E, Brown JP, et al.- Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children. J Clin Densitom, 2004, 7, 51-64.
American Association of Clinical Endocrinologists.-Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients. 2002 update. Endocr Pract, 2002, 8, 440-456.
Agence Nationale d'Accréditation et d'Évaluation en Santé (ANAES).- Ees indications des mesures quantitatives du tissu osseux: actualisation. http://www.anaes.fr/anaes/Publications.nsf/nPDFFile/R A_LILF-548DGR/$File/osteoactu.pdf?OpenElement
Kanis JA, Devogelaer JP, Gennari C.- Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European Foundation for Osteoporosis and Bone Disease. The Scientific Advisory Board and the Board of National Societies. Osteoporos Int, 1996, 6, 256-261.
Baltas, C S. Balanika, A P. Raptou, et al.- Clinical practice guidelines proposed by the Hellenic Foundation of Osteoporosis for the management of osteoporosis based on DXA results. J Musculoskelet Neuronal Interact, 2005, 5, 388-392.
Fuleihan GE, Baddoura R, Awada H, et al.- Lebanese guidelines for osteoporosis assessment and treatment: who to test? What measures to use? When to treat? J Clin Densitom, 2005, 8, 148-163.
American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis.- Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum, 2001, 44, 1496-1503.
Royal College of Physicians.- Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: Royal College of Physicians, 2002.
UK Royal College of Physician.- Bone and Tooth Society: guidelines on prevention and treatment of osteoporosis. London: Royal College of Physicians, 1999.
Richy F, Gourlay M, Ross PD, et al.- Validation and comparative evaluation of the osteoporosis self-assessment tool (OST) in a Caucasian population from Belgium. Q J Med, 2004, 97, 39-46.
Kanis JA, Johnell O, Oden A, et al- Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int, 2001, 12, 989-995.
Gillet P, Reginster JY.- Increased number of hip fractures. Lancet, 1999, 353, 2160-2161.
Van der Klift M, De Laet CE, McCloskey EY et al.-The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res, 2002, 7, 1051-1056.
De Laet CE, van Hout BA, Burger H, et al.- Bone density and risk of hip fracture in men and women: cross sectional analysis. Br Med J, 1997, 315, 221-225.
Johnell O, Kanis JA, Oden A, et al.- Predictive value of BMD for hip and other fractures. J Bone Miner Res, 2005, 20, 1185-1194.
De Laet C, Kanis JA, Oden A, et al.- Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int, 2005, 16, 1330-1338.
Roy DK, O'Neill TW, Finn JD, et al.- Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int, 2003, 14, 19-26.
Willig R, Luukinen H, Jalovaara P.- Factors related to occurrence of hip fracture during a fall on the hip. Public Health, 2003, 117, 25-30.
Kanis J, Johnell O, Gullberg B, et al.- Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporos Int, 1999, 9, 45-54.
van der Voort DJ, Brandon S, Dinant GJ et al.- Screening for osteoporosis using easily obtainable biometrical data: diagnostic accuracy of measured, self-reported and recalled BMI, and related costs of bone mineral density measurements. Osteoporos Int, 2000, 11, 233-239.
Siminoski K, Warshawski RS, Jen H, et al.- The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women. Osteoporos Int, 2006, 17, 290-296.
Birrell F, Pearce MS, Francis RM, et al.- Self-report overestimates true height loss: implications for diagnosis of osteoporosis. Clin Rheumatol, 2005, 24, 590-592.
Sinaki M, Brey RH, Hughes CA, et al.- Balance disorder and increased risk of falls in osteoporosis and kyphosis: significance of kyphotic posture and muscle strength. Osteoporos Int, 2005, 16, 1004-1010.
Kritz-Silverstein D, Barrett-Connor E.- Early menopause, number of reproductive years, and bone mineral density in postmenopausal women. Am J Public Health, 1993, 83, 983-988.
Johnell O, Kanis JA, Oden A et al.- Fracture risk following an osteoporotic fracture. Osteoporos Int, 2004, 15, 175-179.
Lindsay R, Pack S, Li Z.- Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis. Osteoporos Int, 2005, 16, 306-312.
Keen RW, Hart DJ, Arden NK, et al.- Family history of appendicular fracture and risk of osteoporosis: a population-based study. Osteoporos Int, 1999, 10, 161-166.
Pavlov L, Gamble GD, Reid IR.- Comparison of dual-energy X-ray absorptiometry and conventional radiography for the detection of vertebral fractures. J Clin Densitom, 2005, 8, 379-385.
Gordon CM, Nelson LM.- Amenorrhea and bone health in adolescents and young women. Curr Opin Obstet Gynecol, 2003, 15, 377-384.
Wilkins CH, Birge SJ.- Prevention of osteoporotic fractures in the elderly. Am J Med, 2005, 118, 1190-1195.
Suzuki Y, Akima H, Igawa S, et al.- Decrease of bone mineral density and muscle and/or strength in the leg during 20 days horizontal bed rest. J Gravit Physiol, 1996, 3, 42-43.
Ohshima H.- Bone loss and bone metabolism in astronauts during long-duration space flight. Clin Calcium, 2006, 16, 81-85.
Sedlak CA, Doheny MO, Estok PJ, et al.- Tailored interventions to enhance osteoporosis prevention in women. Orthop Nurs, 2005, 24, 270-276.
Baheiraei A, Pocock NA, Eisman JA, et al.- Bone mineral density, body mass index and cigarette smoking among Iranian women: implications for prevention. BMC Musculoskelet Disord, 2005, 6, 34.
Demirbag D, Ozdemir F, Ture M.- Effects of coffee consumption and smoking habit on bone mineral density. Rheum Int, 2005, 1-6.
Kanis JA, Johnell O, Oden A, et al.- Smoking and fracture risk: a meta-analysis. Osteoporos Int, 2005, 16, 155-162.
Kanis JA, Johansson H, Johnell O et al.- Alcohol intake as a risk factor for fracture. Osteoporos Int, 2005, 16, 737-472.
Hoidrup S, Gronbaek M, Gottschau A, et al.- Alcohol intake, beverage preference, and risk of hip fracture in men and women. Copenhagen Centre for Prospective Population Studies. Am J Epidemiol, 1999, 149, 993-1001.
Kanis JA, Johansson H, Oden A, et al.- A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res, 2004, 19, 893-899.
Richy F, Bousquet J, Ehrlich GE, et al.- Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int, 2003, 14, 179-190.
El O, Gulbahar S, Ceylan E, et al.- Bone mineral density in asthmatic patients using low dose inhaled glucocorticosteroids. J Investig Allergol Clin Immunol, 2005, 15, 57-62.
Richy F, Ethgen O, Bruyere O, et al.- Primary prevention of osteoporosis: Mass screening scenario or prescreening with questionnaires? An economic perspective. J Bone Miner Res, 2004, 19, 1955-1960.
Neuprez A, Gillet P, Collette C, et al.- L'ostéodensitomé trie dans le dépistage de l'ostéoporose: le paradoxe belge. Rev Med Liege, 2006, in press.
Baran DT. Faulkner KG. Genant HK, et al.- Diagnosis and management of osteoporosis: guidelines for the utilization of bone densitometry. Calcif Tissue Int, 1997, 61, 433-440.
WHO Study Group.- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health organization Technical Report Series 843, WHO, Geneva, 1994.
Cummings SR, Palermo L, Browner W, et al.- Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA, 2000, 283, 1318-1321.
Hochberg MC, Greenspan S, Wasnich RD, et al.-Changes in bone density, and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab, 2002, 87, 1586-1592.
Delmas PD, Li Z, Cooper C.- Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with metaanalyses. J Bone Miner Res, 2004, 19, 330-337.
Hochberg MC, Ross PD, Black D, et al.- Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum, 1999, 42, 1246-1254.
Watts NB, Geusens P, Barton IP, et al.- Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res, 2005, 20, 2097-2104.
Sarkar S, Mitlak BH, Wong M, et al.- Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res, 2002, 17, 1-10.
Reginster JY, Sarkar S, Zegels B, et al.- Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone, 2004, 34, 344-351.
Neer RM, Arnaud CD, Zanchetta JR, et al.- Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344, 1434-1441.
Reginster JY, Seeman E, De Vernejoul MC, et al.-Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab, 2005, 90, 2816-2822.
Boonen S, Body JJ, Boutsen Y, et al.- Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int, 2005, 16, 239-254.
Bruyère O, Roux C, Cannata JB, et al.- Associations between increase in bone mineral density and decrease in clinical vertebral fracture incidence during a treatment with strontium ranelate. Osteoporos Int, 2006, 17 23.
Chen P, Miller P, Delmas PD, et al.- Teriparatide-mdeiated changes in bone mineral density (BMD) and fracture risk reduction in women with osteoporosis. Osteoporos Int, 2006, 17, 24.
Eastell R, Krege JH, Chen Peigi, et al. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin, 2006, 22, 61-66.
Reginster JY, Rabenda V.- Adherence to treatment in osteoporosis influence on efficiency. Rev Med Suisse, 2005, 1, 2278-2281.
Reginster JY, Rabenda V, Neuprez A.- Adherence, patient preference and dosing frequency: understanding the relationship. Bone, 2006, in press.
